【ChiCTR-ONC-13003015】Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
ChiCTR-ONC-13003015
正在进行
/
/
/
2013-01-22
/
/
Atrial Fibrillation
Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
To assess the effect and safety of Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation.
连续入组
Ⅳ期
NA
/
SK Yee Funding, CUHK
/
80
/
2013-02-28
1990-01-01
/
1. Adults above the age of 18; 2. Non-valvular AF, at high risk of stroke and who have experienced serious bleeding events or repeated nuisance bleed events whilst on warfarin or NOACs; 3. Non-valvular AF, at high risk of stroke and who are intolerant of, has significant side effect, or decline to take warfarin or NOACs; 4. Non-valvular AF, at high risk of stroke and who are poorly compliant with warfarin (Time in therapeutic range <60%) or NOACs; 5. Non-valvular AF, at high risk of stroke and who are at high risk of bleeding as evidenced by a high HAS-BLED score.；
请登录查看1. Inability to take Aspirin and Clopidogrel; 2. Inability to give informed consent; 3. Patients unlikely to benefit from the therapy due to a short life expectancy; 4. NYHA 4; 5. LVEF <30%; 6. Moderate-to-severe or worse mitral or aortic valvular regurgitation or stenosis; 7. Suspected or known intracardiac thrombus; 8. Symptomatic carotid disease.；
请登录查看SK Yee Funding, CUHK
/
SK Yee Funding, CUHK的其他临床试验
research nurse, Division of Cardiology, Department of Medicine & Therapeutics, PWH的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04